Article Text

Download PDFPDF
DNA-content in endometrial carcinoma of tamoxifen-treated breast cancer patients
  1. B. Moberger*,
  2. T. Fornander and
  3. A-C. HellstrÖM
  1. * Department of Obstetrics and Gynecology, Karolinska Hospital;
  2. Department of Oncology, Södersjukhuset; and
  3. Department of Gynecological Oncology, Radiumhemmet, Stockholm, Sweden
  1. Address for correspondence: Dr Birgitta Moberger, Department of Obstetrics and Gyneolcogy, Karolinska Hospital, S-104 01 Stockholm, Sweden.


DNA measurements and histopathologic evaluation were performed in 17 patients treated with adjuvant tamoxifen for early breast cancer and who developed endometrial carcinoma during or after the tamoxifen therapy. The tumors were exclusively characterized by euploid DNA content except for two cases, one mixed mesodermal sarcoma, a highly malignant and rare tumor, and one adenocarcinoma. Although the use of adjuvant tamoxifen therapy most likely enhances the risk of developing endometrial carcinoma, the beneficial effects of adjuvant breast cancer treatment is of well-known clinical importance. The hazards of giving long-term tamoxifen seem to be low since the endometrial tumors were associated with low-grade malignancy and euploid DNA pattern.

  • breast cancer
  • DNA-content
  • endometrial carcinoma
  • tamoxifen.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.